OPTIMYSTIQUE Trademark
Serial Number: 79371564 • Registration: 7307556
OPTIMYSTIQUE is a trademark filed by
UPL LIMITED
on December 19, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals).
The application is currently registered and active.
Trademark Classes
Owner Contact Info
Legal Representation
Correspondence Address
Naresh Kilaru Finnegan, Henderson, Farabow, et al.
901 New York Avenue NW
Washington
DC 20001
UNITED STATES
Trademark Details
Filing Date
December 19, 2022
Registration Date
February 20, 2024
Published for Opposition
December 5, 2023
Filing History
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 11, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 18, 2024 FICS
FINAL DISPOSITION PROCESSED
Jul 18, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 21, 2024 FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 21, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 20, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 20, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 5, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 5, 2023 PUBO
NOTIFICATION PROCESSED BY IB
Dec 4, 2023 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 15, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 15, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 15, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 27, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 21, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 20, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 20, 2023 TROA
REFUSAL PROCESSED BY IB
Aug 29, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 4, 2023 RFCS
REFUSAL PROCESSED BY MPU
Aug 4, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 28, 2023 RFCR
NON-FINAL ACTION WRITTEN
Jun 27, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 22, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 13, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 9, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 8, 2023 REPR
